Analyst Ratings For Tocagen Inc (NASDAQ:TOCA)
Today, B. Riley initiated coverage on Tocagen Inc (NASDAQ:TOCA) with a Buy with a price target of $22.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Tocagen Inc (NASDAQ:TOCA) is Buy with a consensus target price of $22.80 per share, a potential 186.79% upside.
Some recent analyst ratings include
- 12/31/2018-Tocagen Inc (NASDAQ:TOCA) has coverage initiated with a Buy rating and $22.00 price target
- 9/4/2018-Tocagen Inc (NASDAQ:TOCA) has coverage initiated with a Buy rating and $27.00 price target
- 8/30/2018-Tocagen Inc (NASDAQ:TOCA) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- 6/27/2018-Tocagen Inc (NASDAQ:TOCA) has coverage initiated with a Buy rating and $20.00 price target
- 7/25/2017-Tocagen Inc (NASDAQ:TOCA) had its Buy rating reiterated by Stifel Nicolaus with a $24.00 price target
- 5/15/2017-Tocagen Inc (NASDAQ:TOCA) has coverage initiated with a Mkt Perform rating and $19.00 price target
- On 4/19/2017 Asha Das, SVP, bought 2,500 with an average share price of $10.00 per share and the total transaction amounting to $25,000.00.
- On 4/19/2017 Harry E Gruber, Insider, bought 25,000 with an average share price of $10.00 per share and the total transaction amounting to $250,000.00.
- On 4/19/2017 Mark G Foletta, CFO, bought 5,000 with an average share price of $10.00 per share and the total transaction amounting to $50,000.00.
- On 4/19/2017 Paul Schimmel, Director, bought 10,000 with an average share price of $10.00 per share and the total transaction amounting to $100,000.00.
About Tocagen Inc (NASDAQ:TOCA)
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Recent Trading Activity for Tocagen Inc (NASDAQ:TOCA)
Shares of Tocagen Inc closed the previous trading session at 7.95 up +0.86 12.13% with 6.99 shares trading hands.